Research and Markets: Status Epilepticus Pipeline Review, H2 2015 Featuring Ligand Pharmaceuticals, Inc. & Sage Therapeutics
September 04 2015 - 12:36PM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/78thhn/status) has
announced the addition of the "Status Epilepticus - Pipeline
Review, H2 2015" report to their offering.
This report provides comprehensive information on the
therapeutic development for Status Epilepticus, complete with
comparative analysis at various stages, therapeutics assessment by
drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in
the therapeutic development for Status Epilepticus and special
features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to
create effective counter strategies to gain competitive advantage.
It strengthens R&D pipelines by identifying new targets and
MOAs to produce first-in-class and best-in-class products.
Companies Mentioned
- Ligand Pharmaceuticals, Inc.
- Sage Therapeutics
For more information visit
http://www.researchandmarkets.com/research/78thhn/status
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150904005600/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Central Nervous System